Bristol-Myers Squibb and Vedanta Biosciences announce a new clinical collaboration
Bristol-Myers and Vedanta Biosciences announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo with Vedanta’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers. December 10, 2018